Prolastin-C Liquid
Biological
Grifols USA, LLC
Total Payments
$3.1M
Transactions
75,968
Doctors
13,285
Companies
6
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $615,600 | 12,845 | 5,130 |
| 2023 | $542,679 | 13,587 | 5,078 |
| 2022 | $689,777 | 12,295 | 4,618 |
| 2021 | $512,970 | 12,104 | 4,222 |
| 2020 | $294,956 | 8,708 | 3,052 |
| 2019 | $368,298 | 11,189 | 3,988 |
| 2018 | $87,359 | 5,239 | 2,727 |
| 2017 | $21.26 | 1 | 1 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $1.5M | 74,624 | 49.1% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $960,317 | 632 | 30.9% |
| Unspecified | $284,230 | 71 | 9.1% |
| Travel and Lodging | $143,639 | 567 | 4.6% |
| Consulting Fee | $135,550 | 44 | 4.4% |
| Education | $48,223 | 26 | 1.5% |
| Honoraria | $12,092 | 4 | 0.4% |
Payments by Type
General
$2.8M
75,897 transactions
Research
$284,230
71 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Multi-Center, Single-Dose and Repeat-Dose Over Eight Weeks, Sequential Cohort Study to Evaluate Safety and Tolerability as Well as Pharmacokinetics of Two Different Doses of Alpha1-Proteinase Inhibitor Subcutaneous Human 15 Administered Subcutaneousl | Grifols Biologicals LLC | $146,296 | 0 |
| Application of Isogenic CRISPR-Corrected Patient iPSCs to Determine Whether ZATT-Induced Gain of Function Toxicity Renders MZ or ZZ Lung Epithelium Susceptible to Cigarette Smoke Injury | Grifols Shared Services North America, Inc. | $60,750 | 0 |
| Application of Isogenic CRISPR-corrected Patient iPSCs to Determine Whether ZAAT-Induced Gain of Function Toxicity Renders MZ or ZZ Lung Epithelium Susceptible to Cigarette Smoke Injury | Grifols Shared Services North America, Inc. | $40,500 | 0 |
| An Open-Label, Multicenter Study to Evaluate the Long-term Safety of Weekly Intravenous Alpha1-Proteinase Inhibitor (Human), Modified Process 60 mg/kg in Subjects With Pulmonary Emphysema Due to Alpha1-Antitrypsin Deficiency | Grifols Therapeutics LLC | $15,022 | 0 |
| A Randomized, Double-Blind, Placebo Controlled Study to Assess the Efficacy and Safety of Two Dose Regimens (60 mg/kg and 120 mg/kg) of Weekly Intravenous Alpha1 Proteinase Inhibitor (Human) in Subjects With Pulmonary Emphysema Due to Alpha1 Antitrypsin Deficiency | Grifols Therapeutics LLC | $7,372 | 0 |
| A Multicenter, Randomized, Double-blind, Placebo-Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of Liquid Alpha1-Proteinase Inhibitor Human Plus Standard Medical Treatment SMT Versus Placebo Plus SMT in Hospitalized Subjects With | Grifols Therapeutics LLC | $115.07 | 0 |
Top Doctors Receiving Payments for Prolastin-C Liquid
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Phoenix, AZ | $335,789 | 122 |
| Douglas Hogarth | Pulmonary Disease | Chicago, IL | $123,170 | 171 |
| , MD | Critical Care Medicine | Anderson, IN | $85,499 | 98 |
| , MD | Internal Medicine | Pensacola, FL | $58,767 | 90 |
| , M.D | Pulmonary Disease | Pittsburgh, PA | $55,739 | 92 |
| , M.D | Pulmonary Disease | Hazard, KY | $55,247 | 151 |
| , DO | Pulmonary Disease | East Setauket, NY | $48,826 | 93 |
| , MD | Critical Care Medicine | Phoenix, AZ | $46,387 | 62 |
| , M.D., M.SC | Critical Care Medicine | Los Angeles, CA | $43,794 | 49 |
| , DO | Pulmonary Disease | Manasquan, NJ | $41,644 | 78 |
| , MD | Pulmonary Disease | Pittsburgh, PA | $40,777 | 56 |
| , MD | Critical Care Medicine | Buffalo, NY | $37,239 | 74 |
| , M.D | Pulmonary Disease | New York, NY | $36,039 | 61 |
| Michael Zlupko | Pulmonary Disease | Altoona, PA | $34,566 | 121 |
| , M.D | Critical Care Medicine | Fall River, MA | $30,971 | 92 |
| , MD | Pulmonary Disease | Phoenix, AZ | $21,660 | 52 |
| , MD | Pulmonary Disease | Fayetteville, NY | $21,260 | 80 |
| , MD | Pulmonary Disease | Sanford, NC | $20,739 | 22 |
| , DO | Allergy & Immunology | Hershey, PA | $20,708 | 36 |
| , M.D | Pulmonary Disease | Brewster, NY | $19,899 | 49 |
| , M.D | Internal Medicine | Valhalla, NY | $18,367 | 53 |
| , M.D., PH.D | Pulmonary Disease | Denver, CO | $17,453 | 26 |
| , M.D | Allergy & Immunology | Hawthorne, NY | $15,392 | 51 |
| , M.D | Internal Medicine | Miami, FL | $13,597 | 44 |
| , M.D | Critical Care Medicine | Galloway, NJ | $13,435 | 66 |
Ad
Manufacturing Companies
- Grifols USA, LLC $2.7M
- Grifols Shared Services North America, Inc. $202,077
- Grifols Biologicals LLC $146,296
- Grifols Therapeutics LLC $22,509
- Grifols, S.A. $3,092
- Grifols Canada Ltd. $2,576
Product Information
- Type Biological
- Total Payments $3.1M
- Total Doctors 13,285
- Transactions 75,968
About Prolastin-C Liquid
Prolastin-C Liquid is a biological associated with $3.1M in payments to 13,285 healthcare providers, recorded across 75,968 transactions in the CMS Open Payments database. The primary manufacturer is Grifols USA, LLC.
Payment data is available from 2017 to 2024. In 2024, $615,600 was paid across 12,845 transactions to 5,130 doctors.
The most common payment nature for Prolastin-C Liquid is "Food and Beverage" ($1.5M, 49.1% of total).
Prolastin-C Liquid is associated with 6 research studies, including "A Multi-Center, Single-Dose and Repeat-Dose Over Eight Weeks, Sequential Cohort Study to Evaluate Safety and Tolerability as Well as Pharmacokinetics of Two Different Doses of Alpha1-Proteinase Inhibitor Subcutaneous Human 15 Administered Subcutaneousl" ($146,296).